Dr Renly Lim grew up in Malaysia, completed her pharmacy degree in Scotland, her PhD in Malaysia, and has work experience in the UK, Malaysia, Thailand and Cambodia. She is an Associate Research Professor at the Quality Use of Medicines and Pharmacy Research Centre.
Renly's research focuses on advancing the pharmacy profession to improve quality use of medicines, integrating digital health to detect and prevent medicine harms, identifying associations between medicine use and health outcomes, health program evaluation and community engagement.
Renly is an internationally recognised leader in pharmacy and medicine safety. She is the 2021-22 President of the International Pharmaceutical Federation Young Pharmacists Group (FIP YPG) where she led a team of 45 pharmacists and pharmaceutical scientists from 21 countries. FIP is the global peak pharmacy body representing >4 million pharmacists and pharmaceutical scientists. In 2023, she was appointed to the FIP Policy Committee on Access to Medicines, where she helped develop a policy statement on improving access to medicines. The statement was approved by the FIP Council in 2024 and has been adopted by FIP’s 158 national pharmacy organisations across 108 countries. As a Board member of the FIP Data and Intelligence Commission, she contributes to delivering FIP’s data-driven initiatives that are transforming pharmacy practice worldwide and driving global pharmacy workforce reform.
Renly has secured $15 million in research funding, including an NHMRC Ideas Grant as Lead Investigator (2023–26), and has produced over 100 outputs, including peer-reviewed publications, policy documents, and technical reports for organisations including the World Health Organization, Wellcome Trust and the Australian Government Department of Health.